MedTrace Logo

Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

NCT01008683 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2009-11-06

No results posted yet for this study

Summary

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

In these patients the investigators will measure the specific antibody production.

Conditions

  • H1N1 Influenza

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Dan Engelhard · Hadassah

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-04-30
Completion
2010-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01008683 on ClinicalTrials.gov